JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Fate Therapeutics Inc

Closed

SectorHealthcare

0.92

Overview

Share price change

24h

Current

Min

0.89

Max

0.96

Key metrics

By Trading Economics

Income

15M

-38M

Sales

-231K

1.6M

Profit margin

-2,309.454

Employees

181

EBITDA

4.3M

-38M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+397.83% upside

Dividends

By Dow Jones

Next Earnings

18 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-1.1M

122M

Previous open

0.92

Previous close

0.92

News Sentiment

By Acuity

27%

73%

62 / 374 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Fate Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 Aug 2025, 17:49 UTC

Major Market Movers

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 Aug 2025, 17:18 UTC

Major Market Movers

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 Aug 2025, 16:25 UTC

Earnings

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 Aug 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 Aug 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 Aug 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 Aug 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 Aug 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 Aug 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 Aug 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 Aug 2025, 20:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 Aug 2025, 20:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 Aug 2025, 20:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 Aug 2025, 20:22 UTC

Earnings

Exodus Movement 2Q Rev $25.8M >EXOD

11 Aug 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 Aug 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 Aug 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 Aug 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 Aug 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 Aug 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 Aug 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 Aug 2025, 16:42 UTC

Acquisitions, Mergers, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 Aug 2025, 16:27 UTC

Acquisitions, Mergers, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 Aug 2025, 16:26 UTC

Acquisitions, Mergers, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 Aug 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 Aug 2025, 16:25 UTC

Acquisitions, Mergers, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

397.83% upside

12 Months Forecast

Average 4.58 USD  397.83%

High 12 USD

Low 1 USD

Based on 12 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

12 ratings

3

Buy

9

Hold

0

Sell

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Very Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

62 / 374 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.